Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

1.

Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: Comparative study between complete cytoreductive surgery and maximal tumor debulking.

Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ.

Eur J Surg Oncol. 2014 Sep 6. pii: S0748-7983(14)01079-8. doi: 10.1016/j.ejso.2014.09.002. [Epub ahead of print]

PMID:
25238953
[PubMed - as supplied by publisher]
2.

Advances in the management of peritoneal mesothelioma.

Raza A, Huang WC, Takabe K.

World J Gastroenterol. 2014 Sep 7;20(33):11700-12. doi: 10.3748/wjg.v20.i33.11700.

PMID:
25206274
[PubMed - in process]
Free PMC Article
3.

Peritoneal Surface Disease with Synchronous Hepatic Involvement Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI.

Ann Surg Oncol. 2014 Aug 14. [Epub ahead of print]

PMID:
25120252
[PubMed - as supplied by publisher]
4.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.

McConnell YJ, Mack LA, Gui X, Carr NJ, Sideris L, Temple WJ, Dubé P, Chandrakumaran K, Moran BJ, Cecil TD.

Ann Surg Oncol. 2014 Jun;21(6):1975-82. doi: 10.1245/s10434-013-3469-5. Epub 2014 Jan 8.

PMID:
24398544
[PubMed - in process]
5.

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, Turco LC, Bottoni C, Scambia G.

Gynecol Oncol. 2014 Feb;132(2):303-6. doi: 10.1016/j.ygyno.2013.12.028. Epub 2013 Dec 27.

PMID:
24378877
[PubMed - indexed for MEDLINE]
6.

Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei.

Berkovic P, van de Voorde L, De Meerleer G, Delrue L, Speleers B, Van Belle S, Vandecasteele K.

Strahlenther Onkol. 2014 Feb;190(2):223-8. doi: 10.1007/s00066-013-0470-7. Epub 2013 Dec 6.

PMID:
24306063
[PubMed - indexed for MEDLINE]
7.

Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.

Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ.

Dis Colon Rectum. 2013 Dec;56(12):1366-72. doi: 10.1097/DCR.0b013e3182a62b0d.

PMID:
24201390
[PubMed - indexed for MEDLINE]
8.

Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.

Robella M, Vaira M, Marsanic P, Mellano A, Cinquegrana A, Sottile A, De Simone M.

Minerva Chir. 2013 Dec;68(6):551-8.

PMID:
24193287
[PubMed - indexed for MEDLINE]
9.

Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma.

Kelly KJ, Nash GM.

J Surg Oncol. 2014 Jan;109(1):14-22. doi: 10.1002/jso.23449. Epub 2013 Oct 24. Review.

PMID:
24166680
[PubMed - indexed for MEDLINE]
10.

Ovarian cancer: a brief historical overview of intraperitoneal trials.

Kwa M, Muggia F.

Ann Surg Oncol. 2014 May;21(5):1429-34. doi: 10.1245/s10434-013-3219-8. Epub 2013 Oct 1.

PMID:
24081795
[PubMed - indexed for MEDLINE]
11.

Intrathoracic gastric volvulus as a severe, delayed surgical complication after left subphrenic peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer.

Caronna R, Sammartino P, Framarino ML, Sollazzo BM, Meniconi RL, Chirletti P.

World J Surg Oncol. 2013 Sep 23;11:239. doi: 10.1186/1477-7819-11-239.

PMID:
24060198
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G.

Gynecol Obstet Fertil. 2013 Sep;41(9):493-8. doi: 10.1016/j.gyobfe.2013.07.011. Epub 2013 Aug 21. French.

PMID:
23972918
[PubMed - indexed for MEDLINE]
13.

Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.

Järvinen P, Ristimäki A, Kantonen J, Lepistö A.

Scand J Surg. 2013;102(3):145-51. doi: 10.1177/1457496913490463.

PMID:
23963027
[PubMed - in process]
14.

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.

Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):711-9. doi: 10.4161/cbt.25310. Epub 2013 Jun 13.

PMID:
23792567
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

PMID:
22972909
[PubMed - indexed for MEDLINE]
Free Article
16.

Ureteral stenting in cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy as a routine procedure: evidence and necessity.

Coccolini F, Lotti M, Manfredi R, Catena F, Vallicelli C, De Iaco PA, Da Pozzo L, Frigerio L, Ansaloni L.

Urol Int. 2012;89(3):307-10. doi: 10.1159/000339920. Epub 2012 Aug 1.

PMID:
22868250
[PubMed - indexed for MEDLINE]
17.

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model.

Passot G, Dupré A, Rivoire M, Mohamed F, Bakrin N, Glehen O.

Clin Transl Oncol. 2012 Dec;14(12):931-6. doi: 10.1007/s12094-012-0888-x. Epub 2012 Jul 24.

PMID:
22855172
[PubMed - indexed for MEDLINE]
18.

Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.

J Clin Oncol. 2012 Jul 10;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21.

PMID:
22614976
[PubMed - indexed for MEDLINE]
Free Article
19.

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.

Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.

Int J Gynecol Cancer. 2012 Jun;22(5):778-85. doi: 10.1097/IGC.0b013e31824d836c.

PMID:
22572845
[PubMed - indexed for MEDLINE]
20.

Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, Kusamura S.

BJOG. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x.

PMID:
22571746
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk